EP0457875A4 - Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen - Google Patents
Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigenInfo
- Publication number
- EP0457875A4 EP0457875A4 EP19910900650 EP91900650A EP0457875A4 EP 0457875 A4 EP0457875 A4 EP 0457875A4 EP 19910900650 EP19910900650 EP 19910900650 EP 91900650 A EP91900650 A EP 91900650A EP 0457875 A4 EP0457875 A4 EP 0457875A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- human
- specificity
- antibody
- tumor cell
- cell antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43501289A | 1989-11-13 | 1989-11-13 | |
US435012 | 1989-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0457875A1 EP0457875A1 (en) | 1991-11-27 |
EP0457875A4 true EP0457875A4 (en) | 1993-03-03 |
Family
ID=23726623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19910900650 Withdrawn EP0457875A4 (en) | 1989-11-13 | 1990-11-13 | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0457875A4 (ko) |
JP (1) | JPH03206886A (ko) |
KR (1) | KR910009284A (ko) |
AU (1) | AU634314B2 (ko) |
CA (1) | CA2044590A1 (ko) |
WO (1) | WO1991007418A1 (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
AU2610097A (en) * | 1996-04-10 | 1997-10-29 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
IT1289608B1 (it) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
CZ304942B6 (cs) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
AU2002365196C1 (en) | 2001-07-19 | 2009-08-13 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
AU2003243226A1 (en) | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
EP2748613B1 (en) | 2011-10-07 | 2021-05-05 | Baxalta GmbH | Oxmif as a diagnostic marker |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3268046A4 (en) | 2015-03-13 | 2018-11-21 | Endocyte, Inc. | Conjugates for treating diseases |
EP4323017A1 (en) | 2021-04-16 | 2024-02-21 | Novartis AG | Folate receptor-targeted radiotherapeutic agents and their use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323806A1 (en) * | 1988-01-05 | 1989-07-12 | Ciba-Geigy Ag | Novel chimeric antibodies |
EP0323805A2 (en) * | 1988-01-05 | 1989-07-12 | Buchegger, Franz | Novel antibodies |
EP0332424A2 (en) * | 1988-03-09 | 1989-09-13 | Hybritech Incorporated | Chimeric antibodies directed against human carcinoembryonic antigen |
EP0125023B1 (en) * | 1983-04-08 | 1991-06-05 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor |
-
1990
- 1990-11-13 AU AU66641/90A patent/AU634314B2/en not_active Ceased
- 1990-11-13 WO PCT/US1990/006620 patent/WO1991007418A1/en not_active Application Discontinuation
- 1990-11-13 JP JP2308453A patent/JPH03206886A/ja active Pending
- 1990-11-13 CA CA002044590A patent/CA2044590A1/en not_active Abandoned
- 1990-11-13 KR KR1019900018568A patent/KR910009284A/ko not_active Application Discontinuation
- 1990-11-13 EP EP19910900650 patent/EP0457875A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023B1 (en) * | 1983-04-08 | 1991-06-05 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor |
EP0323806A1 (en) * | 1988-01-05 | 1989-07-12 | Ciba-Geigy Ag | Novel chimeric antibodies |
EP0323805A2 (en) * | 1988-01-05 | 1989-07-12 | Buchegger, Franz | Novel antibodies |
EP0332424A2 (en) * | 1988-03-09 | 1989-09-13 | Hybritech Incorporated | Chimeric antibodies directed against human carcinoembryonic antigen |
Non-Patent Citations (1)
Title |
---|
See also references of WO9107418A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1991007418A1 (en) | 1991-05-30 |
AU634314B2 (en) | 1993-02-18 |
KR910009284A (ko) | 1991-06-28 |
AU6664190A (en) | 1991-05-23 |
EP0457875A1 (en) | 1991-11-27 |
JPH03206886A (ja) | 1991-09-10 |
CA2044590A1 (en) | 1991-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0457875A4 (en) | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen | |
ZA8891B (en) | Chimeric antibody with specificity to human b cell surface antigen | |
IL93840A0 (en) | Novel monoclonal antibody to novel antigen associated with human tumors | |
AU4725485A (en) | Monoclonal antibody to a human carcinoma tumor associated antigen | |
AU1085488A (en) | Monoclonal antibodies to a pan-malarial antigen | |
IL89489A0 (en) | Chimeric antibodies directed against human carcinoembryonic antigen | |
EP0415920A4 (en) | Monoclonal antibody specific to hiv antigens | |
GB8820099D0 (en) | Novel chimeric antibodies | |
HK156695A (en) | Novel chimeric antibodies | |
ZA887771B (en) | Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes | |
HK21795A (en) | Cross-protective human monoclonal antibody compositions | |
AU627591B2 (en) | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen | |
EP0208902A3 (en) | Monoclonal antibody specific for a pigmentation associated antigen | |
ZA852426B (en) | Monoclonal antibody specific for human basal cell surface antigen | |
EP0453561A4 (en) | Chimeric mouse human antibodies with specificity to hiv antigens | |
EP0159025A3 (en) | Monoclonal antibody specific to human alpha2-plasmin | |
AU6609686A (en) | Detection of human cancer with a monoclonal antibody specific for antigen 9p650 | |
EP0205046A3 (en) | Monoclonal antibody to human protein c | |
GB8808586D0 (en) | Monoclonal antibody to enteroviruses | |
IE880021L (en) | Antibodies with specificity to human b cell surface antigen | |
ZA856281B (en) | Monoclonal antibody to a human carcinoma tumor associated antigen | |
IE902008L (en) | HUMAN MONOCLONAL ANTIBODIES TO HIV-IMN gp120 | |
IL106425A0 (en) | Chimeric antibodies directed against human carcinoembryonic antigen | |
HRP940824B1 (en) | Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods | |
ZA879133B (en) | Monoclonal antibody specific to neutrophils |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19910718 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19930115 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19940808 |
|
R18W | Application withdrawn (corrected) |
Effective date: 19940808 |